Clinical Trial Update: Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1, open-label dose-escalation trial of the CD38-targeted radiopharmaceutical CD38-SADA:177Lu-DOTA Drug Complex in relapsed or refractory non-Hodgkin lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CD38-SADA:177Lu-DOTA Drug Complex

Snippet

Sponsor: Y-mAbs Therapeutics | Conditions: Non-hodgkin Lymphoma | Phase 1 | Status: TERMINATED